Pd30-01 Defining Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Comparative Study of Eau and Ibcg Criteria

You have accessJournal of UrologyBladder Cancer: Non-invasive II (PD30)1 May 2024PD30-01 DEFINING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: A COMPARATIVE STUDY OF EAU AND IBCG CRITERIA Pietro Scilipoti, Giulio Avesani, Mattia Longoni, Mario De Angelis, Chiara Re, Alessandro Bertini, Quarta Leonardo, Giusy Burgio, Giuseppe Basile, Giuseppe Rosiello, Francesco Pellegrino, Andrea Necchi, Daniele Raggi, Roberta Lucianò, Renzo Colombo, Giorgio Gandaglia, Umberto Capitanio, Andrea Salonia, Francesco Montorsi, Alberto Briganti, and Marco Moschini Pietro ScilipotiPietro Scilipoti , Giulio AvesaniGiulio Avesani , Mattia LongoniMattia Longoni , Mario De AngelisMario De Angelis , Chiara ReChiara Re , Alessandro BertiniAlessandro Bertini , Quarta LeonardoQuarta Leonardo , Giusy BurgioGiusy Burgio , Giuseppe BasileGiuseppe Basile , Giuseppe RosielloGiuseppe Rosiello , Francesco PellegrinoFrancesco Pellegrino , Andrea NecchiAndrea Necchi , Daniele RaggiDaniele Raggi , Roberta LucianòRoberta Lucianò , Renzo ColomboRenzo Colombo , Giorgio GandagliaGiorgio Gandaglia , Umberto CapitanioUmberto Capitanio , Andrea SaloniaAndrea Salonia , Francesco MontorsiFrancesco Montorsi , Alberto BrigantiAlberto Briganti , and Marco MoschiniMarco Moschini View All Author Informationhttps://doi.org/10.1097/01.JU.0001008848.77629.6f.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The European Association of Urology (EAU) and the International Bladder Cancer Group (IBCG) present different definitions of intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC). This study aims to compare the long-term outcomes of IR patients according to the two classifications. METHODS: We conducted an analysis on 430 NMIBC patients who underwent trans-urethral resection of bladder tumor (TURBT) at a tertiary referral center between 2020 and 2022. EAU IR classification includes non-low and -high risk patients, including pTa high grade patients. IBCG IR classification excludes any type of high grade (HG) tumor. Risk of recurrence and progression was assessed through cumulative incidence curves, stratified for both groups. Additionally, multivariable Cox-regression analysis (MVA) was used to assess predictors of recurrence and progression within the overall IR group (covariates: age, grade, T stage, size, multifocality and adequate treatment (≥ 12 maintenance instillations over 1 year)). RESULTS: In total, 199 and 83 patients were classified as having IR disease according to EAU and IBCG classification, respectively. During a median follow-up of 48 (IQR 32-60) months, 92 recurrence and 29 progression were recorded. Adequate BCG treatment was administered to 114 (57%) and 41 (50%) patients in the EAU and IBCG groups. No statistically significant difference emerged between IR-IBCG and IR-EAU groups in terms of cumulative risk of recurrence at 40 months (30% vs 32%, p=0.3). When considering patients who received adequate BCG treatment, the risk of progression at 40 months was higher in the IR-EAU compared to IR-IBCG group (10% vs. 5%, p=0.03). At MVA, HG/G3 histology (HR 2.54, CI 1.15-5.59, p=0.021) and tumor size≥3 cm (HR 2.49 CI 1.31-4.74, p=0.005) were independent predictors of recurrence in the EAU group, while no predictors of recurrence were observed in the IR-IBCG group. CONCLUSIONS: Patients with IR according to IBCG criteria show better oncological outcomes, especially in terms of progression compared to the equivalent EAU class. The presence of HG/G3 tumors and tumor size≥3 may be associated to an increased risk of progression, highlighting the need for their consideration as exclusion criteria for IR disease definition. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e624 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Pietro Scilipoti More articles by this author Giulio Avesani More articles by this author Mattia Longoni More articles by this author Mario De Angelis More articles by this author Chiara Re More articles by this author Alessandro Bertini More articles by this author Quarta Leonardo More articles by this author Giusy Burgio More articles by this author Giuseppe Basile More articles by this author Giuseppe Rosiello More articles by this author Francesco Pellegrino More articles by this author Andrea Necchi More articles by this author Daniele Raggi More articles by this author Roberta Lucianò More articles by this author Renzo Colombo More articles by this author Giorgio Gandaglia More articles by this author Umberto Capitanio More articles by this author Andrea Salonia More articles by this author Francesco Montorsi More articles by this author Alberto Briganti More articles by this author Marco Moschini More articles by this author Expand All Advertisement PDF downloadLoading ...